News Category
Quantum BioPharma receives a 'Buy' rating and $8.00 price target from Rodman & Renshaw, highlighting the potential of its lead candidate Lucid-MS for ...
Earth Science Tech's acquisition of Zoolzy LLC enhances its profit margins, expands ingredient access, and enters the veterinary market, strengthening...
Italian pharmaceutical company DuLac Farmaceutici accelerates its U.S. expansion through new e-commerce channel OneLavi and planned participation in E...
The Alliance for Safe Online Pharmacies warns that retatrutide, an unapproved investigational drug, is being illegally sold online, leading to increas...
VERAXA Biotech's VXA-222 bispecific antibody-drug conjugate program moves to preclinical validation, strengthening its oncology pipeline and intellect...
Onco-Innovations' potential acquisition of an exclusive option on Ifowonco's oral LAG-3 inhibitor program could position the company at the forefront ...
Earth Science Tech's acquisition of Zoolzy is poised to enhance its compounding pharmacy margins and expand into the veterinary therapeutics market, l...
SCHOTT Pharma's parent group's updated climate targets, validated by SBTi, now include a Scope 3 absolute reduction target, shifting focus to value ch...
Helus Pharma reported completion of enrollment in its pivotal Phase 3 APPROACH trial for HLP003 in major depressive disorder, with topline data expect...
VERAXA Biotech's VXA-222 bsADC program moves past discovery phase, and the company expands its IP portfolio with new patent filings, reinforcing its o...
Tonix Pharmaceuticals announced FDA feedback supporting its planned adaptive Phase 2 field study of TNX-4800, a long-acting monoclonal antibody for Ly...
VERAXA Biotech announced the advancement of its bispecific antibody-drug conjugate program VXA-222 after OmniAb completed discovery work, moving the c...
VERAXA Biotech AG appoints Christoph Erkel as CSO to lead development of its BiTAC platform for solid tumor cancer therapies, signaling a strategic pu...
NanoViricides secures $3.8 million from a registered direct offering to advance its broad-spectrum antiviral drug candidate NV-387 and other programs.
VERAXA Biotech AG has appointed Christoph Erkel as CSO to lead the development of its BiTAC platform for solid tumor cancer therapies, leveraging his ...
VERAXA Biotech has received Scientific Advice from Germany's Paul-Ehrlich-Institute supporting its BiTAC-TCE development, reducing uncertainty before ...
VERAXA Biotech AG announced positive regulatory feedback from Germany's Paul-Ehrlich-Institute for its BiTAC-TCE platform, providing clarity on develo...
Siegfried's appointment of Eduardo Montanha as COO, effective September 1, 2026, supports its strategy to offer integrated end-to-end solutions across...
NextPlat Corp agrees to acquire an independent pharmacy near Pensacola, Florida, for $1.5 million to expand its PharmcoRx retail footprint into an und...
Onco-Innovations announced the successful completion of an analytical reference standard program for its lead oncology candidate ONC010, a key step to...
VERAXA Biotech AG has initiated cell line development for its lead BiTAC T-cell engager program by partnering with ATUM, a key step toward IND/CTA-ena...
The global sustained release polymers market is projected to grow from USD 3.8 billion in 2026 to USD 7.8 billion by 2036, fueled by rising chronic di...
VERAXA Biotech AG updated on its BiTAC platform progress, with four T-cell engager programs and two bispecific ADC programs, while seeking partnership...
VERAXA Biotech has started cell line development for its lead BiTAC T-cell engager program, aiming to improve tumor selectivity and reduce off-tumor t...
The article highlights how VERAXA Biotech AG, with its next-generation antibody platform, is poised to benefit from the sustained high level of strate...
Ace Therapeutics announces a full-spectrum preclinical analgesic drug development service with diverse in vivo pain models and integrated research cap...
Medios AG is closing its Aschaffenburg facility and consolidating patient-specific manufacturing to improve profitability, affecting 32 employees, as ...
Helus Pharma announced fiscal 2026 financial results and provided updates on its clinical pipeline, with its lead candidate HLP003 for major depressiv...
Voyageur Pharmaceuticals has hired Fluor Corporation to conduct feasibility studies for an iodine extraction facility in Oklahoma and an integrated co...
Knight Therapeutics has fully repaid its $60 million revolving credit facility drawn to finance the Paladin acquisition, using operational cash flow, ...
Voyageur Pharmaceuticals is analyzing three potential U.S. locations for its vertically integrated contrast media plant, aiming to secure the best inc...
Earth Science Tech Inc. has transformed into a diversified holding company with a vertically integrated telehealth and pharmacy platform, emphasizing ...
Voyageur Pharmaceuticals has submitted a Multi-Year Area-Based Notice of Work application to advance the Frances Creek barite project, including test ...
Voyageur Pharmaceuticals raised $5,005,278.32 through a non-brokered private placement to fund FDA licensing for its barium contrast products, regulat...
Kairos Pharma announced plans to acquire rights to CL-741, a Phase 1-ready oral c-MET inhibitor, and highlighted progress in its oncology pipeline inc...
Quantum BioPharma's lead drug candidate Lucid-MS targets nerve damage in multiple sclerosis, addressing an unmet need, while its commercial product un...
Quantum BioPharma Ltd. (NASDAQ: QNTM) advances a clinical-stage multiple sclerosis program targeting demyelination, differentiating from immune-modula...
Redwood AI Corp. announces DTC eligibility to simplify U.S. trading and liquidity, and hires IBN for a $114,000 investor awareness campaign through Se...
Carmed Pharmaceuticals, a Turkey-based company specializing in standardized carvacrol formulations, is featured in CityBiz as it expands into the U.S....
Sino Biological's new XPressMAX™ Cell-Free Protein Synthesis Kit enables ultra-fast protein and antibody synthesis in just 3 hours, supporting AI-powe...
NanoViricides reported progress in its quarterly filing, highlighting regulatory approval for Phase II MPox trials in the DRC and FDA orphan drug desi...
NanoViricides announced a $2 million registered direct offering to an institutional investor, providing capital for its broad-spectrum antiviral drug ...
Lantern Pharma closed a $4.4 million registered direct offering, using proceeds to advance its AI-driven precision oncology pipeline and expanding its...
Tonix Pharmaceuticals will showcase its commercial and pipeline progress at the RBC Capital Markets Global Healthcare Conference and A.G.P.’s Annual V...
Lantern Pharma's expansion of its predictBBB platform into a Large Quantitative Model enhances drug discovery by providing real-time, web-based molecu...
LIXTE Biotechnology’s first-in-class PP2A inhibitor LB-100 is advancing through clinical trials for solid tumors with high unmet need, offering a nove...
Soligenix leverages its synthetic hypericin platform across multiple dermatologic indications, demonstrating how platform technology can streamline dr...
The shareholders of PolyPeptide Group AG approved all board proposals, including re-election of directors and auditors, at the company's fifth annual ...
